ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
In the biggest CRO takeover in years, ICON doles out $12B for PRA Health Sciences to focus on decentralised clinical work
ICON will acquire PRA Health Sciences for $12 billion in a move that will shake up the hightest rungs of a fragmented market.
Dublin clinical trials group ICON buys PRA in $12bn deal
The combined company will form the world’s largest contract research organisation, and is to be headquartered at ICON’s Leopardstown campus in Dublin.
Deal watch: ICON, PRA Health form massive CRO In $12bn merger
ICON acquires PRA Health Sciences to form a world-leader CRO.
Decentralised, hybrid or traditional: Choosing the best option for your clinical trial
In this article, EB McLindon offers insights to help sponsors decide which approach is most optimal for a clinical trial.
The current and future landscape of HIV treatments and vaccines
Dr. Caroline Forkin discusses the current status of HIV treatments and potential for researchers to develop a vaccine.
Overcoming IVDR challenges for companion diagnostics
Angela Brown, Global Head and Senior Director, Regulatory Affairs and Nicole Cowan, Director, Project Management, IVD Operations & Strategy, provide expert commentary on overcoming IVDR challenges for companion diagnostics.
Best practices in managing CGT from protocol design to data management
ICON's Tamie Joeckel offers expert commentary on managing and executing CGT clinical trials.
COVID-19 trial of alternating vaccines begins in the UK
Recruitment has begun in the UK for a world-first study to investigate whether using different COVID-19 vaccines for first and second doses is as effective as using the same type of vaccine for both. ICON’s Dr Garrett provides commentary.
No10 launches world's first trial into whether mixing and matching coronavirus vaccines can enhance protection
ICON's Dr. Garrett comments on the UK government's new 'Com-Cov' study of over 800 patients, designed to test mixing doses of the Oxford and Pfizer COVID-19 vaccines, as well as different intervals between doses.
Inside a vaccine trial
Dr. Murphy of ICON, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale.